Biomarker for Rapid Diagnosis of Hemispheric Stroke
Completed
- Conditions
- Acute Stroke
- Registration Number
- NCT00916864
- Lead Sponsor
- Johann Wolfgang Goethe University Hospital
- Brief Summary
The aim of the study is to estimate the diagnostic accuracy of a combined biomarker test (including NMDA-Receptor fragments \[NR2-peptide\] and Glial fibrillary acidic protein) used to differentiate between cerebral ischemia and intracerebral hemorrhage in patients with acute hemispheric stroke.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 250
Inclusion Criteria
- hemiparesis
- at least one sign of cortical involvement (e.g., aphasia, neglect, gaze deviation, reduced level of consciousness)
- hospital admission within 4.5 hours after symptom onset
Exclusion Criteria
- stroke/TIA within the last 3 months
- traumatic brain injury within the last 3 months
- history of brain tumor
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Diagnostic accuracy (sensitivity and specificity for diagnosing cerebral ischemia and intracerebral hemorrhage) 9 months
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the diagnostic accuracy of NMDA-Receptor fragments and Glial fibrillary acidic protein in acute hemispheric stroke?
How does the combined biomarker test in NCT00916864 compare to standard-of-care imaging techniques for differentiating cerebral ischemia and intracerebral hemorrhage?
What patient selection biomarkers are associated with improved diagnostic outcomes using NR2-peptide and GFAP in stroke subtypes?
Are there any known adverse events or management strategies for biomarker-based stroke diagnosis using NMDA-Receptor fragments and GFAP?
What are the potential therapeutic implications of NR2-peptide and GFAP biomarker research for acute stroke treatment development?
Trial Locations
- Locations (1)
Department of Neurology, Goethe-University
🇩🇪Frankfurt am Main, Germany
Department of Neurology, Goethe-University🇩🇪Frankfurt am Main, Germany